Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 5
2019 3
2020 1
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

8 results
Results by year
Filters applied: . Clear all The following term was not found in PubMed: Asurza-Veliz
Page 1
Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia.
Walker Z, Gandolfo F, Orini S, Garibotto V, Agosta F, Arbizu J, Bouwman F, Drzezga A, Nestor P, Boccardi M, Altomare D, Festari C, Nobili F; EANM-EAN Task Force for the recommendation of FDG PET for Dementing Neurodegenerative Disorders. Walker Z, et al. Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1534-1545. doi: 10.1007/s00259-018-4031-2. Epub 2018 May 19. Eur J Nucl Med Mol Imaging. 2018. PMID: 29779045 Free PMC article. Review.
PURPOSE: There are no comprehensive guidelines for the use of FDG PET in the following three clinical scenarios: (1) diagnostic work-up of patients with idiopathic Parkinson's disease (PD) at risk of future cognitive decline, (2) discriminating idiopathic PD from progressi …
PURPOSE: There are no comprehensive guidelines for the use of FDG PET in the following three clinical scenarios: (1) diagnostic work-up of p …
Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia.
Bouwman F, Orini S, Gandolfo F, Altomare D, Festari C, Agosta F, Arbizu J, Drzezga A, Nestor P, Nobili F, Walker Z, Morbelli S, Boccardi M; EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders. Bouwman F, et al. Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1526-1533. doi: 10.1007/s00259-018-4034-z. Epub 2018 May 9. Eur J Nucl Med Mol Imaging. 2018. PMID: 29744573 Free PMC article.